Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 16;10(22):5341.
doi: 10.3390/jcm10225341.

COVID-19 and Diabetes

Affiliations
Review

COVID-19 and Diabetes

Virginia Bellido et al. J Clin Med. .

Abstract

Diabetes mellitus (DM) is one of the most common comorbid conditions in persons with COVID-19 and a risk factor for poor prognosis. The reasons why COVID-19 is more severe in persons with DM are currently unknown although the scarce data available on patients with DM hospitalized because of COVID-19 show that glycemic control is inadequate. The fact that patients with COVID-19 are usually cared for by health professionals with limited experience in the management of diabetes and the need to prevent exposure to the virus may also be obstacles to glycemic control in patients with COVID-19. Effective clinical care should consider various aspects, including screening for the disease in at-risk persons, education, and monitoring of control and complications. We examine the effect of COVID-19 on DM in terms of glycemic control and the restrictions arising from the pandemic and assess management of diabetes and drug therapy in various scenarios, taking into account factors such as physical exercise, diet, blood glucose monitoring, and pharmacological treatment. Specific attention is given to patients who have been admitted to hospital and critically ill patients. Finally, we consider the role of telemedicine in the management of DM patients with COVID-19 during the pandemic and in the future.

Keywords: COVID-19; blood glucose monitoring; diabetes mellitus; glycemic control; hyperglycemia; telemedicine.

PubMed Disclaimer

Conflict of interest statement

V.B. has received speaker/advisory honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esteve, Janssen, Merck, Mundipharma, Novartis, Novo Nordisk, Roche, and Sanofi. A.P. has served as a consultant for or received research support, lecture fees, or travel reimbursement from Sanofi, Almirall, Novo Nordisk, Lilly, MSD, Boehringer Ingel-heim, Esteve, Gilead, Novartis, Abbott, Amgen, Menarini, and Astra Zeneca.

Figures

Figure 1
Figure 1
General recommendations for prevention and management of COVID-19 in persons with diabetes.

References

    1. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS- CoV-2. J. Endocrinol. Investig. 2020;43:867–869. doi: 10.1007/s40618-020-01236-2. - DOI - PMC - PubMed
    1. Roncon L., Zuin M., Rigatelli G., Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J. Clin. Virol. 2020;127:104354. doi: 10.1016/j.jcv.2020.104354. - DOI - PMC - PubMed
    1. Singh A.K., Gupta R., Ghosh A., Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. 2020;14:303–310. doi: 10.1016/j.dsx.2020.04.004. - DOI - PMC - PubMed
    1. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020;109:531–538. doi: 10.1007/s00392-020-01626-9. - DOI - PMC - PubMed
    1. Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H., Knighton P., Holman N., Khunti K., Sattar N., et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822. doi: 10.1016/S2213-8587(20)30272-2. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources